Glycostem is a clinical-stage company, harvesting the power of allogeneic cells like Natural Killer (NK) cells – oNKord® – in the field of cellular immunotherapy. Using our proprietary expansion and differentiation platform, we produce large amounts of effector cells from Umbilical Cord Blood stem cells. Products are composed of high-quality, pure and active cells.
NK-cells will be the new star in the domain of cellular immunotherapy. Due to their tightly regulated “natural killing”, caused by a changed balance between activating and inhibitory cellular signals and antibody dependent cellular cytotoxicity (ADCC).
NK-cells have the capability to control viral infections, target cancer and kill senescent cells. Unfortunately, our immune system can be compromised, allowing tumor cells to escape the immunological control mechanisms. Allogeneic conditions will be able to mitigate this problem. Glycostem’s concept and product pipeline is based on this principle.
The lead product – oNKord® – has been tested for safety and efficacy in a phase I study with Acute Myeloid Leukaemia (AML) patients. oNKord® showed no toxicity, expanded in vivo, migrated to the bone marrow and killed leukemic blasts. Glycostem expects to start pivotal trials in AML and MM plus solid tumours in ‘20/’21.